secwatch.observer — SEC 8-K summary
======================================

Issuer:     FibroBiologics, Inc. (FBLG)
CIK:        0001958777
Form:       8-K
Filed at:   2025-06-16T23:59:59+00:00
Accession:  0001641172-25-015282
Event type: other_material
Sentiment:  neutral
Materiality: 0.65
Item codes: 1.01, 2.03, 3.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

FibroBiologics closes $5M third tranche of $25M SEPA with Yorkville; funds for R&D and diabetic foot ulcer trial
--------------------------------------------------------------------------------

- Third $5M tranche of $15M pre-paid advance drawn; total $15M now under SEPA with YA II PN, Ltd.
- Convertible promissory note: 0% interest (18% on default), matures Dec 20, 2025, convertible at lower of $0.9801 or 94% of 5-day VWAP.
- Proceeds for general corporate purposes, including R&D and Phase 1/2 diabetic foot ulcer trial expected H2 2025.
- Company may sell additional $10M common stock to Yorkville with consent while notes outstanding.
- Conversion limited to 4.99% beneficial ownership cap; prior conversions totaled $5.7M principal at varying prices.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1958777/000164117225015282/0001641172-25-015282-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1958777/000164117225015282/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001641172-25-015282

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer